Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT).

ABSTRACT:

Introduction

Anthracyclines are included in chemotherapy regimens to treat several different types of cancer and are extremely effective. However, it is recognised that a significant side effect is cardiotoxicity; anthracyclines can cause irreversible damage to cardiac cells and ultimately impaired cardiac function and heart failure, which may only be evident years after exposure. The PROACT trial will establish the effectiveness of the ACE inhibitor enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin's lymphoma (NHL) receiving anthracycline-based chemotherapy.

Methods and analysis

PROACT is a prospective, randomised, open-label, blinded end-point, superiority trial which will recruit adult patients being treated for brea

SUBMITTER: Maier RH 

PROVIDER: S-EPMC9809245 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature